Platelet function pathway

The platelet function pathway encompasses the integrated signaling, adhesion, secretion, and aggregation events by which platelets contribute to hemostasis, thrombosis, immune responses, and tissue repair[1][2][4][8]. This pathway coordinates numerous molecular entities, including surface receptors (e.g., P2Y12, PAR1, GPIIb/IIIa), enzymes, signaling mediators, and cytoskeletal elements that respond to vascular injury and other cues. Dysregulation or targeting of specific nodes within this pathway can lead to or treat a variety of diseases such as cardiovascular disorders, cancer metastasis, or immune-mediated platelet disorders. Though it is a major therapeutic axis, "platelet function pathway" itself is not considered a single, canonical drug target but rather a collection of molecular targets relevant for pharmacology and precision medicine.

Other names

Platelet activation pathwayPlatelet signaling pathwayPlatelet aggregation pathway

Drugs act by: - Inhibiting platelet activation or aggregation (e.g., blocking P2Y12, PAR1, or GPIIb/IIIa receptors) - Modulating platelet lifespan and immune-mediated destruction (e.g., TPO receptor agonists, rituximab) - Modifying platelet–cancer cell interactions or immune modulation